Th1-Th2 paradigm: insights from leprosy.

The mechanism by which T cells and cytokines regulate immune processes in skin can be investigated by studying patients with leprosy. The disease, caused by the obligate intracellular bacterium Mycobacterium leprae, forms a spectrum. At one pole, patients with tuberculoid leprosy are able to restrict the growth of the pathogen and their skin lesions are characterized by a predominance of CD4+ T cells and type 1 cytokines including interleukin 2 and interferon gamma. At the opposite pole, patients with lepromatous leprosy are unable to contain the infection and their skin lesions are characterized by a predominance of CD8+ T cells and type 2 cytokines including interleukins 4 and 10. A key determinant of the T-cell cytokine response may be interleukin 12, which selectively favors expansion of CD4+ T cells producing interferon gamma. By understanding the factors that regulate T-cell and cytokine responses in leprosy, it should be possible to devise specific immunologic interventions in diseases of skin.

[1]  T. Ottenhoff,et al.  Molecular localization and polymorphism of HLA class II restriction determinants defined by Mycobacterium leprae-reactive helper T cell clones from leprosy patients , 1986, The Journal of experimental medicine.

[2]  K. Kiene,et al.  CD4+ type 1 and CD8+ type 2 T cell subsets in human leishmaniasis have distinct T cell receptor repertoires. , 1993, Journal of immunology.

[3]  Ridley Ds,et al.  Classification of leprosy according to immunity. A five-group system. , 1966 .

[4]  T. Gajewski,et al.  Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations. , 1991, Journal of immunology.

[5]  P. Hart,et al.  Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[6]  R. Locksley,et al.  TH1 and TH2 cell antigen receptors in experimental leishmaniasis. , 1993, Science.

[7]  R. Daynes,et al.  Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function , 1990, The Journal of experimental medicine.

[8]  H. Murray,et al.  Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-gamma is the activating lymphokine. , 1983, The Journal of clinical investigation.

[9]  K. Weinberg,et al.  Defining protective responses to pathogens: cytokine profiles in leprosy lesions. , 1991, Science.

[10]  J. Convit,et al.  Learning from lesions: patterns of tissue inflammation in leprosy. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[11]  F. Podlaski,et al.  Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). , 1991, Journal of immunology.

[12]  R. Steinman,et al.  The cutaneous infiltrates of leprosy: cellular characteristics and the predominant T-cell phenotypes. , 1982, The New England journal of medicine.

[13]  K. Arai,et al.  Isolation and characterization of a human interleukin cDNA clone, homologous to mouse B-cell stimulatory factor 1, that expresses B-cell- and T-cell-stimulating activities. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[14]  I. Weissman,et al.  Analysis of naturally occurring delayed-type hypersensitivity reactions in leprosy by in situ hybridization , 1989, The Journal of experimental medicine.

[15]  T. Mosmann,et al.  Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[16]  E. Kovacs.  Fibrogenic cytokines: the role of immune mediators in the development of scar tissue. , 1991, Immunology today.

[17]  J. Convit,et al.  Immunological suppression by human CD8+ T cells is receptor dependent and HLA-DQ restricted. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[18]  C. Taylor,et al.  In situ identification of cells in human leprosy granulomas with monoclonal antibodies to interleukin 2 and its receptor. , 1984, Journal of immunology.

[19]  M. de Carli,et al.  Accumulation of Th-2-like helper T cells in the conjunctiva of patients with vernal conjunctivitis. , 1991, Journal of immunology.

[20]  T. Nutman,et al.  Cytokine regulation of antigen-driven immunoglobulin production in filarial parasite infections in humans. , 1990, The Journal of clinical investigation.

[21]  Roberta,et al.  Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. , 1991, The Journal of clinical investigation.

[22]  C. Taylor,et al.  T lymphocyte subsets in the skin lesions of patients with leprosy. , 1983, Journal of the American Academy of Dermatology.

[23]  Kendall A. Smith,et al.  In vivo responses to Mycobacterium leprae: antigen presentation, interleukin-2 production, and immune cell phenotypes in naturally occurring leprosy lesions. , 1985, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

[24]  C. Hayes,et al.  Evidence for differential induction of helper T cell subsets during Trichinella spiralis infection. , 1989, Journal of immunology.

[25]  R. Fernandez-Botran,et al.  Lymphokine-mediated regulation of the proliferative response of clones of T helper 1 and T helper 2 cells , 1988, The Journal of experimental medicine.

[26]  R. Steinman,et al.  The cutaneous infiltrates of leprosy: cellular characteristics and the predominant T-cell phenotypes. , 1982, The New England journal of medicine.

[27]  J. Simon,et al.  Low dose ultraviolet B-irradiated Langerhans cells preferentially activate CD4+ cells of the T helper 2 subset. , 1990, Journal of immunology.

[28]  M. Piccinni,et al.  Allergen- and bacterial antigen-specific T-cell clones established from atopic donors show a different profile of cytokine production. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. Coffman,et al.  Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. , 1986, Journal of immunology.

[30]  P. Scott,et al.  Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice , 1993, The Journal of experimental medicine.

[31]  R. Schaub,et al.  Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response , 1993, The Journal of experimental medicine.

[32]  T. Kasahara,et al.  Interleukin 2-mediated immune interferon (IFN-gamma) production by human T cells and T cell subsets. , 1983, Journal of immunology.

[33]  C. Nathan,et al.  Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity , 1983, The Journal of experimental medicine.

[34]  C. Hsieh,et al.  Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. , 1993, Science.

[35]  H. Remold,et al.  IL-4 inhibits H2O2 production and antileishmanial capacity of human cultured monocytes mediated by IFN-gamma. , 1989, Journal of immunology.

[36]  G. Kaplan,et al.  The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2 , 1989, The Journal of experimental medicine.

[37]  J. Convit,et al.  Determination of the cytokine profile in American cutaneous leishmaniasis using the polymerase chain reaction , 1993, Clinical and experimental immunology.

[38]  S. Carding,et al.  MHC control of CD4+ T cell subset activation , 1989, The Journal of experimental medicine.

[39]  G. Rook,et al.  Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. , 1986, Immunology.

[40]  J. Abrams,et al.  Immunosuppressive roles for IL-10 and IL-4 in human infection. In vitro modulation of T cell responses in leprosy. , 1993, Journal of immunology.

[41]  C. Taylor,et al.  Serum and tissue lysozyme in leprosy , 1977, Infection and Immunity.

[42]  C. Crawford.  Mechanisms of reaction in leprosy. , 1972, The Lancet.

[43]  T. Godal,et al.  Mechanism of "reactions" in borderline tuberculoid (BT) leprosy. A preliminary report. , 1973, Acta pathologica et microbiologica Scandinavica. Supplement.

[44]  F. Liew,et al.  Nonspecific defence mechanism: the role of nitric oxide. , 1991, Immunology today.

[45]  C. Taylor,et al.  In situ characterization of T lymphocyte subsets in the reactional states of leprosy. , 1983, Clinical and experimental immunology.

[46]  R. Locksley,et al.  Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets , 1989, The Journal of experimental medicine.

[47]  F. Aronson,et al.  IL-4 inhibits IL-2 receptor expression and IL-2-dependent proliferation of human T cells. , 1990, Journal of immunology.

[48]  J. Convit.  The Kellersberger Memorial Lecture: leprosy and leishmaniasis similar clinical-immunological-pathological models. , 1974, Ethiopian medical journal.

[49]  A. Sher,et al.  Downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, Schistosoma mansoni , 1991, The Journal of experimental medicine.

[50]  R. Coffman,et al.  Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens , 1988, The Journal of experimental medicine.

[51]  T. Mosmann,et al.  Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. , 1990, Science.

[52]  J. Berzofsky,et al.  Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. , 1993, Science.

[53]  G. Trinchieri,et al.  Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells , 1993, The Journal of experimental medicine.

[54]  A. Sher,et al.  Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[55]  B. Bloom,et al.  Genetically restricted suppressor T-cell clones derived from lepromatous leprosy lesions , 1986, Nature.

[56]  J. Convit,et al.  Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. , 1991, Science.

[57]  D. Ridley,et al.  Lymphocyte transformation test in leprosy; correlation of the response with inflammation of lesions. , 1976, Clinical and experimental immunology.

[58]  A. Limaye,et al.  Regulation of parasite-induced eosinophilia: selectively increased interleukin 5 production in helminth-infected patients , 1990, The Journal of experimental medicine.

[59]  R. Rerko,et al.  Recombinant interleukin 12 cures mice infected with Leishmania major , 1993, The Journal of experimental medicine.

[60]  Michael Loran Dustin,et al.  Adhesion of T lymphoblasts to epidermal keratinocytes is regulated by interferon gamma and is mediated by intercellular adhesion molecule 1 (ICAM-1) , 1988, The Journal of experimental medicine.

[61]  B. Bloom,et al.  Suppressor T lymphocytes from lepromatous leprosy skin lesions. , 1986, Journal of immunology.

[62]  S. Romagnani.  Induction of TH1 and TH2 responses: a key role for the 'natural' immune response? , 1992, Immunology today.

[63]  B. Bloom,et al.  Cytokine patterns of immunologically mediated tissue damage. , 1992, Journal of immunology.

[64]  R. Steinman,et al.  Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. , 1986, The New England journal of medicine.

[65]  H. Jansen,et al.  Evidence for compartmentalization of functional subsets of CD2+ T lymphocytes in atopic patients. , 1990, Journal of immunology.

[66]  D. Ridley,et al.  Classification of leprosy according to immunity. A five-group system. , 1966, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

[67]  C. Pirmez,et al.  Cytokine patterns in the pathogenesis of human leishmaniasis. , 1993, The Journal of clinical investigation.